Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

Inclusion Criteria:

- Able to understand and willing to sign the informed consent form (ICF)

- Healthy subjects 18-70 years of age

- If of childbearing potential, agree to use protocol-specified contraception

- Body mass index (BMI) 19.0-32.0 kg/m^2

- Blood pressure ≤ 139/89 mm Hg

- Subjects are able to follow the study protocol and complete the trial

Exclusion Criteria:

- Current use of tobacco or nicotine-containing products or illicit drug use

- History of severe allergic or anaphylactic reaction to a therapeutic drug or severe
seasonal allergies

- Any known pulmonary disease

- Use of any prescription, investigational drugs, herbal supplements, or nonprescription
drugs within 1 month or 5 half-lives (whichever is longer) prior to study drug
administration, or dietary supplements within 1 week prior to study drug
administration, unless, in the opinion of the Investigator and Sponsor, the medication
will not interfere with the study

- Abnormal hematological and chemistry laboratory values >10% above upper limit of
normal (ULN) or >10% below the lower limit of normal (LLN). Absolute neutrophil count
(ANC) ≤ 1000 cells/mm^3

- Use of any biologic drugs in the last 120 days prior to dosing.

- Immunization with a live or attenuated vaccine within 4 weeks prior to study drug
administration

- Prior treatment with any biologic anti-GM-CSF or GM-CSF receptor antagonists

- ADA screening positive

- Subjects who have a history of documented autoimmune disease, even if not clinically
severe or never treated with systemic steroids or immunosuppressive agents

- A positive alcohol test and/or urine drug screen for substance of abuse at screening
or upon check-in to the clinical site